China
Africa
Explore chapters and articles related to this topic
Osteonecrosis of the Jaws Associated with the Use of Bisphosphonates: A Review of 63 Cases
Published in Niall MH McLeod, Peter A Brennan, 50 Landmark Papers every Oral & Maxillofacial Surgeon Should Know, 2020
Another area to consider in the often-used bisphosphonate-related osteonecrosis of the jaws (BRONJ) terminology is that this has now been changed to antiresorptive drug-related osteonecrosis of the jaws (ARONJ) and medication-related osteonecrosis of the jaw (MRONJ).5,6 This reflects the association of necrosis with the emergence of newer drugs such as denosumab that have a different mode of action and pharmacotherapeutics profile.
Oral Mucosal Reactions to Anticancer Therapies
Published in Gabriella Fabbrocini, Mario E. Lacouture, Antonella Tosti, Dermatologic Reactions to Cancer Therapies, 2019
Emmanuelle Vigarios, Vincent Sibaud
The association of antiresorptive drugs (bisphosphonates, e.g., zoledronic acid, pamidronate, and the inhibitor of RANKL [receptor activator of nuclear factor κB ligand] [denosumab]) with antiangiogenic targeted therapies (sunitinib, bevacizumab) significantly increases the risk of developing medication-related osteonecrosis of the jaw (65), most often after oral surgery (Tables 8.1 and 8.7).
Benign Oral and Dental Disease
Published in John C Watkinson, Raymond W Clarke, Terry M Jones, Vinidh Paleri, Nicholas White, Tim Woolford, Head & Neck Surgery Plastic Surgery, 2018
Konrad S. Staines, Alexander Crighton
Osteonecrosis of the jaws may develop secondary to irradiation to the head and neck. In recent years there has been an increased incidence of medication related osteonecrosis of the jaw secondary to use of antiresorptive drugs such as but not exclusively, bisphosphonates and denosumab.
Platelet rich plasma in oral and maxillofacial surgery from the perspective of composition
Published in Platelets, 2021
Eduardo Anitua, Sofía Fernández-de-Retana, Mohammad H. Alkhraisat
Furthermore, the application of PRP has also been evaluated in the prevention and treatment of medication-related osteonecrosis of the jaw (MRONJ) and osteoradionecrosis). A systematic review concluded that there is not enough evidence to support the application of PRP in the treatment of MRONJ. Importantly, the composition of PRP was not evaluated [35]. Regarding the types of PRP, there is poor evidence supporting the efficacy of L-PRP in the management of these pathological situations. An RCT did not observe any beneficial effect of applying an L-PRP to prevent the occurrence of osteoradionecrosis [36]. Similarly, two non-controlled studies evaluated the efficacy of L-PRP as adjuvant therapy [37,38], reporting success rates ranging from 50% to 83.3%. Finally, another RCT described that the addition of laser therapy and L-PRP to surgical and pharmaceutical treatment of MRONJ resulted in lower bone exposure [39] (Figure 3).
Porphyromonas, Treponema, and Mogibacterium promote IL8/IFNγ/TNFα-based pro-inflammation in patients with medication-related osteonecrosis of the jaw
Published in Journal of Oral Microbiology, 2021
Qingxiang Li, Yinfei Pu, Han Lu, Ning Zhao, Yifei Wang, Yuxing Guo, Chuanbin Guo
Medication-related osteonecrosis of the jaw (MRONJ) is the progressive death of the jaw caused by long-term application of antiresorptive and/or antiangiogenic drugs. Diagnosis of MRONJ is performed based on patient’s pharmacological history as well as clinical and radiographic features (judgment of the jawbone or mucosal or cutaneous fistula that perforated the jawbone) [1]. Low bone turnover, bone and soft tissue toxicity, microfractures, inflammation, and infection are all possible causes of MRONJ [2–4]. Microorganisms in the oral cavity can directly affect the jawbone through an odontogenic infection, like pulpitis or periodontitis [5]. Previous studies have suggested that surgical and dental treatment may promote bacteria colonization and further stimulate the immune response [6].
Salivary metabolomics for cancer detection
Published in Expert Review of Proteomics, 2020
Salivary metabolomics analysis has been used for cancer detection, as well as for predicting and monitoring the therapy response. Yatsuoka et al. found that salivary hypotaurine could predict medication-related osteonecrosis of the jaw in cancer patients treated with bone-modifying agents [65]. Although the metabolomic profiles of other biofluids have been used for predicting the efficacy of adjuvant treatments such as chemotherapy [66], there are few reports of these applications using saliva.